New drug cocktail shows promise for Hard-to-Treat leukemia
NCT ID NCT02879695
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a combination of three immunotherapy drugs (blinatumomab, nivolumab, and ipilimumab) in 28 adults with a severe form of B-cell leukemia that had returned or not responded to prior treatments. The main goal was to find safe doses and identify side effects. While the approach aims to help the immune system fight the cancer, this is not a cure study—patients may need ongoing treatment or face relapse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD19+ PRECURSOR B-ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
Yale University
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells outsmart resistant blood cancers?
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- Can a pill make CAR T-Cell therapy last longer?
- New combo attack on stubborn leukemia: chemo then transplant
- Smart drug hunts down hidden leukemia cells
- New cocktail of cancer drugs shows promise in early leukemia trial